ArticleBMC infectious diseases2026
Chikungunya outbreak in eastern Senegal, 2023.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChikungunya virus (CHIKV) is a mosquito-borne Alphavirus that has caused several epidemics around the world in recent years. CHIKV is endemic in eastern Senegal, particularly in Kédougou, where epidemiological and virological surveillance is implemented in combination with the 4S network. In August 2023, an outbreak was reported in Kédougou, which rapidly spread to Tambacounda. Epidemiological and virological investigations were carried out in both regions by teams from the Institut Pasteur de Dakar, the WHO, the Africa CDC and the Senegalese Ministry of Health.
methodsThe team first visited residential areas of confirmed cases, then a definition of suspected cases including socio-demographic aspects and clinical signs was used in an active door-to-door search for other cases. The blood samples were tested for CHIKV infection by real-time RT-PCR and anti-CHIKV IgM ELISA. Continuous variables were described using mean ± SD or median (IQR), and categorical variables as percentages with 95% confidence intervals, with group comparisons via Pearson’s χ2 or Fisher’s exact test. Kruskal–Wallis tests assessed differences in age across case categories. A multivariate logistic regression (variables with p < 0.25 in bivariate analysis, manual topdown stepwise selection) was fitted, and model fit evaluated using the Hosmer–Lemeshow test with interaction terms retained at p < 0.05.
resultsOut of 1070 blood samples tested, 315 confirmed cases were identified, resulting in an infection rate of 29.4%. There were no deaths. Under 15 and 15–30 age groups, male gender, headache, myalgia, joint pain, asthenia, and retro-orbital pain were among the factors associated with these cases.
conclusionsThe present study provides clinical and epidemiological characteristics of CHIKV-positive cases, emphasizing the large geographical extension of the epidemic. It outlines the largest chikungunya outbreak documented in Senegal to date, hypothesizes sylvatic transmission, and describes the changing epidemiologic profile of CHIKV. It also stresses that a One-Health strategy is of primary importance in effectively controlling zoonoses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.